Histogen Receives Decision To Grant European Patent Titled ‘CASPASE INHIBITORS AND METHODS OF USE THEREOF (FOR THE TREATMENT OF VARIOUS DISEASES)’
https://register.epo.org/application?number=EP20716287
Sermonix Pharmaceuticals Shares Additional Findings From Its Evaluation Of Lasofoxifene In ESR1 Mutations Phase 2 Study At The 4th Annual Congress Of The ISLB NOTE: Sermonix Licensed Lasofoxifene Globally From Ligand Pharmaceuticals
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today shared additional
Aligos Therapeutics To Present Nonclinical And Clinical Data For Its Chronic Hepatitis B And NASH Portfolio At AASLD’s The Liver Meeting 2022 November 4-8
Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced seven upcoming
BriaCell Announces Completion Of Phase I Portion Of Clinical Study In Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing
BriaCell has successfully completed its Phase I safety and tolerability evaluation of Bria-IMT™ in combination with Incyte's retifanlimab in advanced breast cancer.
The combination treatment showed a
Matinas BioPharma Announces Interim Data From The Phase 2 EnACT Trial Of MAT2203 For The Treatment Of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival In All-Oral Cohort 4 Regimen Currently 90%
Two-week survival in Cohort 4 (all-oral regimen) was 95% in 40 patients receiving MAT2203
Mean Early Fungicidal Activity (EFA) of the rate of yeast clearance in cerebrospinal fluid exceeded
Silverback Therapeutics Announced FDA’s Acceptance of ARS Pharmaceuticals’ NDA for Neffy (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) Including Anaphylaxis
Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback") today announced that the U.S.
Abiomed Completes All Impella Post-Approval Studies For High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock And Right Heart Failure
Abiomed (NASDAQ:ABMD) announces the U.S. Food and Drug Administration (FDA) has accepted and closed the post-approval study reports related to the pre-market approvals (PMA) for Impella heart pumps. The
Novocure Announces Review Article Of Anti-cancer Mechanisms Of Action Of Tumor Treating Fields Published In Journal Of Molecular Cell Biology
Novocure Announces Review Article of Anti-Cancer Mechanisms of Action of Tumor Treating Fields Published in Journal of Molecular Cell Biology
A fast-growing body of research, both in vitro and in vivo, is converging to
Incyte Corporation Announces Late Wednesday Phase 3 Data Showing Improvements In Facial And Total Body Repigmentation With Ruxolitinib Cream In Vitiligo Published In New England Journal Of Medicine
Data served as basis for recent FDA approval of ruxolitinib cream (Opzelura™) 1.5% for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older
Fifty-two